Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer
Authors:
- Masashi AndoMAMasashi Ando
- Norikazu MasudaNMNorikazu Masuda
- Kenjiro AogiKAKenjiro Aogi
- Hiroyo InoHIHiroyo Ino
- Hiroji IwataHIHiroji Iwata
- Yutaka TokudaYTYutaka Tokuda
- Naohito YamamotoNYNaohito Yamamoto
- Hiroi KasaiHKHiroi Kasai
- Masahiko TakeuchiMTMasahiko Takeuchi
- Hitoshi TsudaHTHitoshi Tsuda
- Futoshi AkiyamaFAFutoshi Akiyama
- 1 February 2012
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 12 (1) , 49-56
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialThe Lancet, 2007
- Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other FactorsJournal of Clinical Oncology, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 WeeksJournal of Clinical Oncology, 2005
- American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer OutcomeJNCI: Journal of the National Cancer Institute, 2005
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902Journal of Clinical Oncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998